Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Halozyme Therapeutics
HALO
5
Lantheus
LNTH
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 13.92%-22.53M | 13.22%-4.56M | 18.51%-5.68M | -3.65%-8.17M | 32.06%-4.13M | -5.12%-26.18M | 16.84%-5.25M | -8.19%-6.96M | -23.75%-7.88M | -5.15%-6.08M |
Net income from continuing operations | 18.97%-23.73M | 22.52%-4.62M | 19.65%-7.2M | 14.82%-6.19M | 19.39%-5.72M | 3.45%-29.28M | 24.84%-5.96M | -4.19%-8.96M | -5.81%-7.27M | -2.37%-7.1M |
Operating gains losses | -84.62%2K | --0 | ---- | ---- | ---- | -70.45%13K | --0 | ---- | ---- | ---- |
Depreciation and amortization | 5.06%166K | -5.00%38K | 22.50%49K | -32.50%27K | 36.84%52K | 7.48%158K | 5.26%40K | 11.11%40K | 5.26%40K | 8.57%38K |
Other non cash items | 36.61%306K | -62.13%89K | 2,020.00%96K | 2,266.67%65K | 1,966.67%56K | 1,823.08%224K | 5,975.00%235K | -66.67%-5K | 0.00%-3K | 0.00%-3K |
Change In working capital | -831.23%-2.51M | -102.72%-596K | -29.17%845K | -153.89%-3.62M | 236.19%864K | -113.12%-269K | -138.89%-294K | -10.10%1.19M | -281.02%-1.43M | -24.63%257K |
-Change in receivables | 32.79%567K | -20.81%236K | --0 | 1,511.11%290K | -54.44%41K | 270.80%427K | 219.20%298K | --21K | 1,900.00%18K | 8,900.00%90K |
-Change in inventory | 16.34%-932K | 98.83%-13K | ---243K | ---726K | --50K | ---1.11M | ---1.11M | --0 | --0 | --0 |
-Change in prepaid assets | 315.79%451K | -79.38%86K | 51.20%316K | 69.29%-207K | 259.01%256K | -126.52%-209K | -3.92%417K | -39.77%209K | 37.13%-674K | -114.92%-161K |
-Change in payables and accrued expense | -142.90%-1.1M | -89.63%120K | -15.94%364K | -340.18%-2.45M | 1,732.08%865K | 938.62%2.56M | 1,907.81%1.16M | 428.03%433K | 878.85%1.02M | -115.68%-53K |
-Change in other current assets | 65.85%-14K | 1,800.00%17K | -63.16%-31K | ---- | ---- | 18.00%-41K | 97.73%-1K | -1,800.00%-19K | ---- | ---- |
-Change in other current liabilities | 91.56%-265K | 54.06%-1.06M | -23.68%419K | 84.20%-279K | 71.39%653K | -338.53%-3.14M | -438.68%-2.3M | -50.67%549K | -990.12%-1.77M | 220.95%381K |
-Change in other working capital | -197.12%-1.22M | --16K | --20K | ---251K | ---1M | --1.25M | ---- | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 13.92%-22.53M | 13.22%-4.56M | 18.51%-5.68M | -3.65%-8.17M | 32.06%-4.13M | -5.12%-26.18M | 16.84%-5.25M | -8.19%-6.96M | -23.75%-7.88M | -5.15%-6.08M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 87.50%-8K | 61.54%-5K | 125.00%3K | 0 | 53.85%-6K | -100.41%-64K | -101.62%-13K | -100.36%-12K | -100.52%-26K | -100.20%-13K |
Net PPE purchase and sale | 87.50%-8K | 61.54%-5K | 125.00%3K | --0 | 53.85%-6K | 39.05%-64K | 38.10%-13K | 45.45%-12K | -30.00%-26K | 69.05%-13K |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 87.50%-8K | 61.54%-5K | 125.00%3K | --0 | 53.85%-6K | -100.41%-64K | -101.62%-13K | -100.36%-12K | -100.52%-26K | -100.20%-13K |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 12.62%24.33M | -67.93%1.19M | -56.07%76K | 182.20%22.9M | -98.29%164K | 854.91%21.6M | 1,052.48%3.71M | -90.99%173K | 42,600.00%8.11M | 9.6M |
Net common stock issuance | 12.62%24.33M | -67.93%1.19M | -67.73%91K | 182.02%22.88M | -98.27%164K | 854.91%21.6M | 1,052.48%3.71M | -85.46%282K | --8.11M | --9.49M |
Proceeds from stock option exercised by employees | ---- | ---- | ---- | --15K | --0 | ---- | ---- | ---- | --0 | --109K |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 12.62%24.33M | -67.93%1.19M | -56.07%76K | 182.20%22.9M | -98.29%164K | 854.91%21.6M | 1,052.48%3.71M | -90.99%173K | 42,600.00%8.11M | --9.6M |
Net cash flow | ||||||||||
Beginning cash position | -43.14%6.12M | 46.98%11.27M | 16.56%16.87M | -84.97%2.15M | -43.14%6.12M | -39.13%10.76M | -51.90%7.67M | -15.31%14.47M | -22.63%14.27M | -39.13%10.76M |
Current changes in cash | 138.44%1.78M | -117.28%-3.37M | 17.74%-5.6M | 7,152.71%14.72M | -213.19%-3.97M | 32.89%-4.64M | 70.09%-1.55M | -494.67%-6.8M | 115.00%203K | 357.63%3.51M |
End cash Position | 29.16%7.9M | 29.16%7.9M | 46.98%11.27M | 16.56%16.87M | -84.97%2.15M | -43.14%6.12M | -43.14%6.12M | -51.90%7.67M | -15.31%14.47M | -22.63%14.27M |
Free cash flow | 14.10%-22.54M | 13.34%-4.56M | 18.69%-5.67M | -3.31%-8.17M | 32.10%-4.14M | -4.93%-26.24M | 16.91%-5.26M | -8.00%-6.98M | -23.77%-7.91M | -4.62%-6.09M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |